DocumentsDate added
ORIGINAL ARTICLE
Rajeev Kumar1*,Bandana Sharma2,Swati Trivedi3,Ranbeer Kumar Mehta4
1 Associate Professor, Department of Anaesthesiology, Rama Medical College, Kanpur, Uttar Pradesh, India
2 Department of Obstetrics and Gynecology, G.S.V.M. Medical College, Kanpur,Uttar pradesh, India
3 Assistant Professor, Department of Anaesthesiology, Rama Medical College, Kanpur, Uttar Pradesh, India
4 Professor and HOD, Department of Anaesthesiology, Rama Medical College, Kanpur, Uttar Pradesh, India
Address reprint requests to
*Dr. Rajeev Kumar, Associate Professor, Department of Anaesthesiology, Rama Medical College, Kanpur, Uttar Pradesh, India
Article citation: Kumar R, Sharma B,Trivedi S, Mehta RK. The effect of dexmedetomidine on haemodynamic changes, extubation time and sedation during laparoscopic hysterectomy. J Pharm Biomed Sci 2016;06(03):225–229.Available at www.jpbms.info
ABSTRACT
Background and Aim Suppression of deleterious effect of pneumoperitoneum is a very important goal of laparoscopic surgeries. Dexmedetomidine is a highly selective α2-adrenoreceptor agonist that causes centrally mediated reduction of sympathetic nervous system activity and lead to sedation and analgesia. The aim of our study was to evaluate the effect of dexmedetomidine on haemodynamic response of intraoperative events like laryngoscopy, endotracheal intubation, pneumoperitoneum and extubation time, and sedation during and after laproscopic hysterectomy.
Methods A prospective, randomised and double blind study was done on 50 female patients, undergoing laparoscopic total hysterectomy. All patients were randomly allocated into two groups; group D (dexmedetomidine) and group C (normal saline). Group D
received inj dexmedetomidine 1 μg/kg, diluted in 50 ml of normal saline over 15 min of duration and 0.4 μg/kg/h infusion was started till the pneumoperitoneum continues. Group C patients receive normal saline infusion. Parameter recorded was heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean blood pressure (MAP), SPO2 and ETCO2. Assessment of sedation was done at extubation than every 15 min for 2 h by Ramsay sedation score (RSS).
Results Among haemodynamic profile, mean arterial pressure and HR after drug administration were significantly lower in perioperative period, particularly at intubation and extubation time in dexmedetomidine (group D) as compared with controls (group C). The extubation time was significantly lower in the dexmedetomidine groups than in the control group. No significant change was seen in the sedation score in both the groups.
Conclusion Dexmedetomidine use during laparoscopic hysterectomy leads to attenuation of hemodynamic response to pneumoperitonium and decrease in extubation time with no change in sedation level of the patients.
KEYWORDS dexmedetomidine, laproscopic hysterectomy, pneumoperitonium
REFERENCES
1.Larsen JF, Svendsen FM, Pedersen V. Randomized clinical trial of the effect of pneumoperitoneum on cardiac function and haemodynamics during laparoscopic cholecystectomy. Br J Surg.2004;91(7):848–854.
2.Myre K, Rostrup M, Buanes T, Stokland O. Plasma catecholamines and haemodynamic changes during pneumoperitoneum.Acta Anaesthesiol Scand. 1998;42(3):343–347.
3.Mann C, Boccara G, Pouzeratte Y, Eliet J, Serradel-Le Gal C,Vergnes C, et al. The relationship among carbon dioxide pneumoperitoneum, vasopressin release, and hemodynamic changes. Anesth Analg. 1999;89(2):278–283.
4.Gutt CN, Oniu T, Mehrabi A, Schemmer P, Kashfi A, Kraus T,et al. Circulatory and respiratory complications of carbon dioxide insufflation. Dig Surg. 2004;21:95–105.
5.Mahdavi A, Peiretti M, Dennis S, Nezhat F. Comparison of laparoscopic hysterectomy morbidity for gynecologic, oncologic, and benign gynecologic conditions. JSLS 2006;10:439–442.
6.Toyoyama H, Kariya N, Hase I, Toyoda Y. The use of intravenous nitroglycerin in a case of spasm of the sphincter of Oddi during laparoscopic cholecystectomy. Anesthesiology.2001;94(4):708–709.
7.Koivusalo AM, Scheinin M, Tikkanen I, Yli-Suomu T, Ristkari S,Laakso J, et al. Effects of esmolol on haemodynamic response to CO2 pneumoperitoneum for laparoscopic surgery. Acta Anaesthesiol Scand. 1998;42(5):510–517.
8.Damen SL, Nieuwenhuijs VB, Joosten W, Houweling PL, Clevers GJ. The effects of remifentanil and sufentanil on the quality of recovery after day case laparoscopic cholecystectomy: a randomized blinded trial. J Laparoendosc Adv Surg Tech A. 2004;14(2):87–92.
9.Pandey CK, Priye S, Ambesh SP, Singh S, Singh U, Singh PK. Prophylactic gabapentin for prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy:a randomized, double-blind, placebo-controlled study.J Postgrad Med. 2006;52(2):97–100.
10.Peng PW, Li C, Farcas E, Haley A, Wong W, Bender J, et al. Use of low-dose pregabalin in patients undergoing laparoscopic cholecystectomy. Br J Anaesth. 2010;105(2):155–161.
11.Jee D, Lee D, Yun S, Lee C. Magnesium sulphate attenuates arterial pressure increase during laparoscopic cholecystectomy. Br J Anaesth. 2009;103(4):484–489.
12.Singh M, Choudhury A, Kaur M, Liddle D, Verghese M,Balakrishnan I. The comparative evaluation of intravenous with intramuscular clonidine for suppression of hemodynamic changes in laparoscopic cholecystectomy. Saudi J Anaesth.2013;7(2):181–186.
13.Khanduja S, Ohri A, Panwar M. Dexmedetomidine decreases requirement of thiopentone sodium and pentazocine followed with improved recovery in patients undergoing laparoscopic cholecystectomy. J Anaesthesiol Clin Pharmacol.2014;30(2):208–212.
14.Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic and analgesic properties of smalldose Dex infusions. Anesth Analg. 2000;90:699–705.
15.Carollo DS, Nossaman BD, Ramadhyani U. Dexmedetomidine:a review of clinical applications. Curr Opin Anaesthesiol. 2008;21:457–461.
16.Bloor BC, Ward DS, Belleville JP, Maze M. Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes.Anesthesiology. 1992;77:1134–1142.
17.Isik B, Arslan M, Özsoylar O, Akçabay M. The effects of α2‑adrenergic receptor agonist exmedetomidine on hemodynamic response in direct laryngoscopy. Open Otorhinolaryngol J. 2007;1:5–11.
18.Gurbet A, Basagan‑Mogol E, Turker G, Ugun F, Kaya FN, Ozcan B. Intraoperative infusion of dexmedetomidine reduces perioperative analgesic requirements. Can J Anaesth. 2006;53:646–652.
19.Talke P, Lobo E, Brown R. Systemically administered alpha2-agonist-induced peripheral vasoconstriction in humans. Anesthesiology. 2003;99:65–70.
20.Piascik MT, Soltis EE, Piascik MM, Macmillan LB. Alpha-adrenoceptors and vascular regulation: Molecular, pharmacologic and clinical correlates. Pharmacol Ther. 1996;72:215–241.
21.Grewal A. Dexmedetomidine: New avenues. J Anaesthesiol Clin Pharmacol. 2011;27(3):297–302.
22.Ishii H, Kohno T, Yamakura T, Ikoma M, Baba H. Action of dexmedetomidine on the substantia gelatinosa neurons of the rat spinal cord. Eur J Neurosci. 2008;27(12):3182–3190.
23.Roudet C, Mouchet P, Feuerstein C, Savasta M. Normal distribution of alpha 2-adrenoceptors in the rat spinal cord and its modification after noradrenergic denervation: a quantitative autoradiographic study. J Neurosci Res. 1994;39(3):319–329.
24.Stone LS, Broberger C, Vulchanova L, Wilcox GL, Hökfelt T, Riedl MS, et al. Differential distribution of alpha2A and alpha2C adrenergic receptor immunoreactivity in the rat spinal cord. J Neurosci. 1998;18(15):5928–5937.
25.Arain SR, Ebert TJ. The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation. Anesth Analg. 2002;95(2):461–466.
26.Candiotti KA, Bergese SD, Bokesch PM, Feldman MA, Wisemandle W, Bekker AY; MAC Study Group. Monitored anesthesia care with dexmedetomidine: a prospective, randomized, double-blind, multicenter trial. Anesth Analg. 2010;110(1):47–56.
27.Alex Bekker, Mary K Sturaitis. Dexmedetomidine for neurological surgery. Neurosurgery. 2005;57(1):1–10.
28.Aho M, Erkola O, Kallio A, Scheinin H, Korttila K. Dexmedetomidine for maintenance of anesthesia in patients undergoing abdominal hysterectomy. Anesth Analg. 1992;75:940–946.
29.Parikh DA, Kolli SN, Karnik HS, Lele SS, Tendolkar BA. A prospective randomized double‑blind study comparing dexmedetomidine vs. combination of midazolam–fentanyl for tympanoplasty surgery under monitored anesthesia care. J Anaesthesiol Clin Pharmacol. 2013;29:173–178.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Ting-Mei Wang1,Yi-Fang Li1,Hiroshi Kurihara1,2,Rong-Rong He1*
1 Anti-Stress and Health Research Center,College of Pharmacy, Jinan University, Guangzhou, China
2 Institute of Traditional Chinese Medicine and Natural Products, Jinan University, Guangzhou, China
Address reprint requests to
*Rong-Rong He, PhD, Institute of Traditional Chinese Medicine and Natural Products, Jinan University,Guangzhou, China
Article citation: Wang TM, Li YF, Kurihara H, He RR. Toxicity induced by Madopar (l-DOPA) during curing Parkinson’s disease by inhibiting mitochondrial function and AKT pathway. J Pharm Biomed Sci 2016;06(03):250–254.Available at www.jpbms.info
ABSTRACT
Complexity myelofibrosis diagnosis at an early stage is that it takes place under other conditions mask: anaemia, abdominal pain, enlarged liver and spleen. This article describes
a case of myelofibrosis in a child, when the diagnosis was made late, which resulted in a poor prognosis.
KEYWORDS myelofibrosis, myeloproliferative disorders, acute myeloid leukemia
REFERENCES
1.Dagur G, Warren K, Schwamb R, Dalpiaz A, Gandhi J, Khan S.Neuro-urological manifestations of Parkinson’s disease. Int J Neurosci. 2016;126:481–487.
2.Lindholm D, Mäkelä J, Di Liberto V, Mudo G, Belluardo N,Eriksson O, et al. Current disease modifying approaches to treat Parkinson’s disease. Cell Mol Life Sci. 2016;73:1365–79.
3.Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med. 2013;62:132–144.
4.Ishida Y, Ebihara K, Tabuchi M, Imamura S, Sekiguchi K,Mizoguchi K, et al. Yokukansan, a traditional Japanese medicine, enhances the l-DOPA-induced rotational response in 6-hydroxydopamine-lesioned rats: possible inhibition of COMT. Biol Pharm Bull. 2016;39:104–113.
5.Ghiglieri V, Mineo D, Vannelli A, Cacace F, Mancini M, Pendolino V, et al. Modulation of serotonergic transmission by eltoprazine in l-DOPA-induced dyskinesia: behavioral, molecular, and synaptic mechanisms. Neurobiol Dis. 2016;86:140–153.
6.Park KH, Shin KS, Zhao TT, Park HJ, Lee KE, Lee MK. l-DOPA modulates cell viability through the ERK-c-Jun system in PC12 and dopaminergic neuronal cells. Neuropharmacology. 2016;101:87–97.
7.Nikolaus S, Beu M, de Souza Silva MA, Huston JP, Hautzel H,Mattern C, et al. Relationship between l-DOPA-induced reduction in motor and exploratory activity and striatal dopamine D-2 receptor binding in the rat. Front Behav Neurosci. 2016;10:36.
8.Jang W, Park HH, Lee, KY, Lee YJ, Kim HT, Koh SH. 1,25-dyhydroxyvitamin D-3 attenuates l-DOPA-induced neurotoxicity in neural stem cells. Mol Neurobiol. 2015;51:558–570.
9.Lanzillotta A, Porrini V, Bellucci A, Benarese M, Branca C, Parrella E, et al. NF-kappa B in innate neuroprotection and age-related neurodegenerative diseases. Front Neurol. 2015;6:98.
10.Gangarossa G, Guzman M, Prado VF, Prado MAM, Daumas S, El Mestikawy S, et al. Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia. Neurobiol Dis. 2016;87:69–79.
11.Park HY, Ryu YK, Kim YH, Park TS, Go J, Hwang JH, et al. Gadd45β ameliorates l-DOPA-induced dyskinesia in a Parkinson’s disease mouse model. Neurobiol Dis. 2016;89:169–79.
12.Mu X, Yuan X, Du LD, He GR, Du GH. Antagonism of quercetin against tremor induced by unilateral striatal lesion of 6-OHDA in rats. J Asian Nat Prod Res. 2016;18:65–71.
13.Zhang X, Li Y, Liu C, Fan R, Wang P, Zheng L, et al. Alteration of enteric monoamines with monoamine receptors and colonic dysmotility in 6-hydroxydopamine-induced Parkinson’s disease rats. Transl Res. 2015;166:152–162.
14.Yu ZH, Cai M, Xiang J, Zhang ZN, Zhang JS, Song XL, et al.PI3K/Akt pathway contributes to neuroprotective effect of Tongxinluo against focal cerebral ischemia and reperfusion injury in rats. J Ethnopharmacol. 2016;181:8–19.
15.Feng X, Wu C, Yang M, Liu Q, Li H, Liu J, et al. Role of PI3K/Akt signal pathway on proliferation of mesangial cell induced by HMGB1. Tissue Cell. 2016;48:121–5.
16.Bove J, Martinez-Vicente M, Dehay B, Perier C, Recasens A, Bombrun A, et al. BAX channel activity mediates lysosomal disruption linked to Parkinson disease. Autophagy. 2014;10:889–900.
17.Rekha KR, Selvakumar GP. Gene expression regulation of Bcl2, Bax and cytochrome-C by geraniol on chronic MPTP/ probenecid induced C57BL/6 mice model of Parkinson’s disease. Chem Biol Interact. 2014;217:57–66.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Competing interest / Conflict of interest:The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript. The first two authors contributed equally to the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.